
newsprogestin therapybenign uterine disease
Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study
By MedXY|Aug 18, 2026
A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.